LoadingLoadingLoadingNet selling: insiders sold $13M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (1)
Bridgewater
$12.3M
bought
Sells/Trims (2)
Squarepoint
$46.4M
trimmed
D.E. Shaw
$24.4M
trimmed
No tracked top-trader positions in RPRX as of Oct 24, 09:35 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Financial period
Q2 2026
Earnings per share
$1.27 expected
Revenue
$758.9M expected
FY2026 guidance
$3.40B to $3.50B
No comparable estimate
Estimates as of Oct 24, 2026
EPS expected
$1.15 to $1.22
Revenue expected
4 analysts
Last 30 days
Split both ways
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $1.32 / $1.27Alpha Vantage | +3.94% beat | $773.0M $758.9M expected | +1.86% beat |
| Mar 31, 2026 | May 6, 2026 | $1.30 / $1.18Alpha Vantage | +10.17% beat | $630.6M No estimate | Unavailable |
| Dec 31, 2025 | Feb 11, 2026 | $1.47 / $1.33Alpha Vantage | +10.53% beat | $622.0M No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | $1.17 / $1.11Alpha Vantage | +5.41% beat | $609.3M No estimate | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | $1.14 / $1.03Alpha Vantage | +10.68% beat | $578.7M No estimate | Unavailable |
| Mar 31, 2025 | May 8, 2025 | $1.06 / $0.95Alpha Vantage | +11.58% beat | $568.2M No estimate | Unavailable |
| Dec 31, 2024 | Feb 11, 2025 | $1.15 / $1.05Alpha Vantage | +9.52% beat | $593.6M No estimate | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $1.04 / $0.93Alpha Vantage | +11.83% beat | $564.7M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $609.3M | $622.0M | $630.6M | $674.1M |
| Cost of what it sold | $1.3M | $1.2M | $1.2M | $268.2M |
| Gross profit | $609.3M | $622.0M | $629.4M | $405.9M |
| What it spent | ||||
| Research and development | $50.5M | $51.0M | $40.0M | $97.9M |
| Sales and admin | $118.7M | $164.3M | $159.0M | $161.9M |
| Other operating costs | $12.9M | $18.3M | -$202.1M | $13.1M |
| Total operating expenses | $182.1M | $233.6M | -$3.1M | $272.8M |
| What was left | ||||
| Operating profit | $427.2M | $388.4M | $632.5M | $133.0M |
| Interest on debt | $79.6M | $94.2M | $93.7M | $93.6M |
| Profit before tax | $444.2M | $355.9M | $468.3M | $81.5M |
| Tax | $156.0M | $142.0M | $173.0M | — |
| Net profit | $288.2M | $214.2M | $295.0M | $17.9M |
| EBITDA | $525.1M | $451.3M | $563.1M | $176.4M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Royalty Pharma declares $0.235 dividend for Q4 2026, payable December 10
Leans bullishOct 16Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share
NeutralOct 16Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10.
Leans bullishOct 16Global femtech market to reach $255.5B by 2035, driven by AI, telehealth, and personalized women's healthcare.
BullishOct 15Form 4 Royalty Pharma Plc For: 12 October By Investing.com
NeutralOct 12Royalty Pharma EVP Marshall Urist sells $235,594 in shares
NeutralOct 12Form 4 Royalty Pharma Plc For: 12 October By Investing.com
NeutralOct 12
